Genmab — Maj 2018
-
Impact of Baseline Renal Function on Efficacy and Safety of Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplantation (ALCYONE) — Poster presentation, Friday, June 15, 5:30 PM — 7:00 PM CEST
-
@Bulder Tak for info

-
-
God morgen.

-
God morgen

-
En lærerig artikel om små forsøg https://finance.yahoo.com/news/apos-why-nektar-therapeutics-fell-173800191.html
-
peter12 - dette er positivt for Genmab, da BMS kører opdivo/dara
kombi forsøg i nogle af de samme kræftformer.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
